{
  "metadata": {
    "id": "sample-iva-001",
    "name": "Opdivo MOA Deck",
    "brand": "Opdivo",
    "therapeuticArea": "Oncology",
    "targetAudience": "Medical Oncologists",
    "slideCount": 5,
    "status": "draft",
    "createdAt": "2025-01-15T10:00:00Z",
    "updatedAt": "2025-01-15T12:30:00Z",
    "isFavorite": true
  },
  "slides": [
    {
      "templateId": "title-slide",
      "slots": {
        "headline": "Opdivo (nivolumab)",
        "subhead": "Mechanism of Action and Clinical Data"
      }
    },
    {
      "templateId": "content-image-split",
      "slots": {
        "headline": "How Opdivo Works",
        "body": "Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. By binding to PD-1 receptors on T cells, Opdivo blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.",
        "image": null,
        "isi": "IMPORTANT SAFETY INFORMATION: Severe and fatal immune-mediated adverse reactions can occur..."
      }
    },
    {
      "templateId": "data-chart-focus",
      "slots": {
        "headline": "Overall Survival Data",
        "chart": null,
        "caption": "Data from CheckMate trial. Results may vary.",
        "isi": null
      }
    },
    {
      "templateId": "bullet-list",
      "slots": {
        "headline": "Key Clinical Benefits",
        "bullets": "Improved overall survival in multiple tumor types\nDurable responses in subset of patients\nManageable safety profile with immune-related adverse events\nCombination therapy options available",
        "image": null,
        "isi": null
      }
    },
    {
      "templateId": "three-column",
      "slots": {
        "headline": "Treatment Considerations",
        "column1-title": "Patient Selection",
        "column1-body": "Consider PD-L1 expression status and prior treatments when selecting patients for Opdivo therapy.",
        "column2-title": "Dosing",
        "column2-body": "Refer to prescribing information for recommended dosing schedules by indication.",
        "column3-title": "Monitoring",
        "column3-body": "Regular monitoring for immune-related adverse reactions is recommended throughout treatment.",
        "isi": "Please see full Prescribing Information and Medication Guide for Opdivo."
      }
    }
  ]
}
